144 related articles for article (PubMed ID: 25618424)
1. Immunosuppressive therapy and cancer risk in ocular inflammation patients: fresh evidence and more questions.
Khachatryan N; Kempen JH
Ophthalmology; 2015 Feb; 122(2):219-21. PubMed ID: 25618424
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil for ocular inflammation.
Daniel E; Thorne JE; Newcomb CW; Pujari SS; Kaçmaz RO; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Foster CS; Jabs DA; Kempen JH
Am J Ophthalmol; 2010 Mar; 149(3):423-32.e1-2. PubMed ID: 20042178
[TBL] [Abstract][Full Text] [Related]
3. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
4. Azathioprine for ocular inflammatory diseases.
Pasadhika S; Kempen JH; Newcomb CW; Liesegang TL; Pujari SS; Rosenbaum JT; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Suhler EB
Am J Ophthalmol; 2009 Oct; 148(4):500-509.e2. PubMed ID: 19570522
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate for ocular inflammatory diseases.
Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide for ocular inflammatory diseases.
Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use.
Kim EC; Foster CS
Int Ophthalmol Clin; 2006; 46(2):141-64. PubMed ID: 16770160
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil therapy for inflammatory eye disease.
Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
[TBL] [Abstract][Full Text] [Related]
9. Treatment of ocular inflammatory disorders with daclizumab.
Papaliodis GN; Chu D; Foster CS
Ophthalmology; 2003 Apr; 110(4):786-9. PubMed ID: 12689903
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine for ocular inflammatory diseases.
Kaçmaz RO; Kempen JH; Newcomb C; Daniel E; Gangaputra S; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Foster CS
Ophthalmology; 2010 Mar; 117(3):576-84. PubMed ID: 20031223
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease.
Durrani K; Zakka FR; Ahmed M; Memon M; Siddique SS; Foster CS
Surv Ophthalmol; 2011; 56(6):474-510. PubMed ID: 22117884
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.
Suelves AM; Arcinue CA; González-Martín JM; Kruh JN; Foster CS
Ophthalmology; 2013 Jun; 120(6):1201-9. PubMed ID: 23601800
[TBL] [Abstract][Full Text] [Related]
13. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.
Udoetuk JD; Dai Y; Ying GS; Daniel E; Gangaputra S; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Kempen JH;
Ophthalmology; 2012 Aug; 119(8):1569-74. PubMed ID: 22484116
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic non-infectious uveitis and scleritis.
Rossi DC; Ribi C; Guex-Crosier Y
Swiss Med Wkly; 2019 Feb; 149():w20025. PubMed ID: 30852832
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
Sobrin L; Christen W; Foster CS
Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.
Saw VP; Dart JK; Rauz S; Ramsay A; Bunce C; Xing W; Maddison PG; Phillips M
Ophthalmology; 2008 Feb; 115(2):253-261.e1. PubMed ID: 17655931
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
18. MMF and eye disease.
Zierhut M; Stübiger N; Siepmann K; Deuter CM
Lupus; 2005; 14 Suppl 1():s50-4. PubMed ID: 15803933
[TBL] [Abstract][Full Text] [Related]
19. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.
Letko E; Miserocchi E; Daoud YJ; Christen W; Foster CS; Ahmed AR
Clin Immunol; 2004 Jun; 111(3):303-10. PubMed ID: 15183151
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide or Rituximab Treatment of Scleritis and Uveitis for Patients with Granulomatosis with Polyangiitis.
Ahmed A; Foster CS
Ophthalmic Res; 2019; 61(1):44-50. PubMed ID: 29635229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
